Compare Cassava Sciences Inc (FLNA) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Hershey Co — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Hershey Co trades at $174.13 (market cap $34.54B). The key difference: Hershey Co is far larger — about 650× Cassava Sciences Inc's market cap, and Hershey Co pays a 3.41% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | HSY | |
|---|---|---|
Market Cap | $53.14M | $34.54B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $236.28 |
52-Week Low | $1.09 | $162.31 |
Enterprise Value | -$33.43M | $39.34B |
Dividend Yield | — | 3.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Hershey (HSY) trades at $171.46, down 2.16% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.35 exceeding expectations. Revenue growth remains steady, and the company benefits from easing cocoa costs and margin recovery. Recent corporate actions include a $1.45 dividend payment scheduled for June 2026.
The outlook for HSY is cautiously optimistic, driven by margin improvement and innovation, though near-term price pressure and competitive risks persist. The consensus price target of $209.25 suggests upside potential, but investors should monitor execution on H2 2026 guidance and input cost trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
